The ICRS Newsletter Summer 2019 Issue is now out. Hard copies will be delivered to our members and partners worldwide in the next few days. Enyoy Reading
The ICRS Newsletter Summer 2019 Issue is now out. Hard copies will be delivered to our members and partners worldwide in the next few days. Enyoy Reading
We are extremely proud and honoured to announce our 4 Diamond Partners for the upcoming years. Vericel, Aesculap and Zimmer Biomet renewed the programme and JRF Ortho joined this high level for the first time.
Procedure is part of global clinical trial for technology developed by Israel’s CartiHeal, which hopes to bring relief to millions of sufferers of knee pain
Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?
OR AKIVA, Israel and PRINCETON, New Jersey, August 28, 2017 /PRNewswire/ — Regentis Biomaterials Ltd., a privately held company developing proprietary hydrogels for tissue regeneration, announced today it has received European CE mark approval for its GelrinC® biodegradable implant.
TELTOW, BERLIN, GERMANY / ACCESSWIRE / July 12, 2017 / Today, CO.DON AG received the Commission’s implementing decision of 10.07.2017 on the granting of marketing authorization for the human pharmaceutical product,
European Union (EU) regulators yesterday recommended approval of a third-generation transplant product of autologous cultured cartilage cells for repairing worn-out knees that doesn’t require any scaffold material.
KFAR SABA, Israel, Dec. 20, 2016 /PRNewswire/ — CartiHeal (2009) Ltd., developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application.
Sobi has come to an agreement with TiGenix for the early termination of their existing commercial relationships and will return the distribution rights for ChondroCelect to TiGenix.
CENTENNIAL, Colo., Jan. 19, 2016 /PRNewswire-USNewswire/ — AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, was awarded U.S. Patent Number 9,186,253, titled Cartilage mosaic compositions and methods, for its new cartilage repair allograft, ProChondrix® Cartilage Restoration Matrix.
AlloSource recently joined the ICRS as a corporate member as well as a silver sponsor for the upcoming ICRS world congress Sorrento.
